Thalidomide and thalidomide analogues for induction of remission in Crohn's disease (Q24241766)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Thalidomide and thalidomide analogues for induction of remission in Crohn's disease (English)

0 references

0 references

0 references

Ramesh Srinivasan

1

0 references

Anthony K Akobeng

series ordinal

2

0 references

publication date

15 April 2009

0 references

published in

0 references

cites work

Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Thalidomide and its derivatives: emerging from the wilderness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Thalidomide and lenalidomide in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

THALIDOMIDE AND CONGENITAL ABNORMALITIES

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

New life in a sleeper: thalidomide and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

7 January 2021

Thalidomide in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

7 January 2021

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

7 January 2021

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

7 January 2021

Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

7 January 2021

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007350.PUB2

7 January 2021

10.1002/14651858.CD007350.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4690197

OpenCitations bibliographic resource ID

4690197

1 reference